Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
28 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsNovartis drug crizanlizumab shown to prolong time to patients` first sickle cell pain crisis in subgroup analysis of SUSTAIN study
(WorldNews Switzerland)

 
 

11 december 2017 18:40:48

 
Novartis drug crizanlizumab shown to prolong time to patients` first sickle cell pain crisis in subgroup analysis of SUSTAIN study
(WorldNews Switzerland)
 


Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximatelydoubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN data Results were consistent across patient subgroups despite differences in disease severity, genotype or background therapy New findings for crizanlizumab, a potential disease-modifying, preventive treatment option for patients with sickle cell disease, presented at ASH 2017 Discussions with health authorities continue; FDA filing anticipated by end of 2018 pending outcome of ongoing healthy volunteer bridging study Basel, December 11, 2017 - Results from a post hoc subgroup analysis of the Phase...


 
16 viewsCategory: General > Europe > Switzerland
 
INEOS Forties Pipeline System
(WorldNews Switzerland)
Kuehne + Nagel opens regional Integrated Logistics Control Centre in Shanghai
(WorldNews Switzerland)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten